Research statistics

Tesofensine research: publications and trials

What has been published on Tesofensine: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Tesofensine works or is safe. For what it is and what the studies found, see the Tesofensine profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

39

Since 2001

Publications in 2026 so far

1

Through November 15, 2026

Human clinical research

39.5%

15 of 38 classified

Registered clinical trials

13

ClinicalTrials.gov

Randomized controlled trials

12

Publications reporting an RCT in people

Systematic reviews and meta-analyses

1

Preclinical studies

26.3%

9 animal · 1 in vitro · 0 computational

Records that only mention it

17

Not counted above

Status in the library: In clinical trials. 1 publications are not yet classified by study type.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.
  • Not a peptide: it is shown for completeness and left out of every peptide total.

Publications by year

Tesofensine publications by year and evidence

2001, Reviews and meta-analyses: 1 of 12004, Human clinical research: 1 of 12006, Preclinical (animal, in vitro, computational): 1 of 12007, Human clinical research: 2 of 32007, Preclinical (animal, in vitro, computational): 1 of 32008, Human clinical research: 2 of 42008, Reviews and meta-analyses: 1 of 42008, Other and not yet classified: 1 of 42009, Human clinical research: 2 of 72009, Reviews and meta-analyses: 2 of 72009, Other and not yet classified: 3 of 72010, Human clinical research: 4 of 72010, Preclinical (animal, in vitro, computational): 2 of 72010, Reviews and meta-analyses: 1 of 72011, Human clinical research: 1 of 42011, Preclinical (animal, in vitro, computational): 1 of 42011, Reviews and meta-analyses: 1 of 42011, Other and not yet classified: 1 of 42012, Reviews and meta-analyses: 1 of 12013, Human clinical research: 1 of 42013, Preclinical (animal, in vitro, computational): 2 of 42013, Other and not yet classified: 1 of 42018, Reviews and meta-analyses: 1 of 12022, Human clinical research: 1 of 12024, Preclinical (animal, in vitro, computational): 1 of 12025, Preclinical (animal, in vitro, computational): 2 of 22026 (to date), Human clinical research: 1 of 1Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified0246820012007201020132026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
200100101
200410001
200601001
200721003
200820114
200920237
201042107
201111114
201200101
201312014
201800101
202210001
202401001
202502002
2026 (to date)10001

Study types

Randomized controlled trial12
Animal study9
Review7
Editorial, letter or other5
Other clinical trial3
In vitro study1
Meta-analysis1
Not yet classified1

Research areas

From MeSH major topics. A paper can be in several areas.

Obesity and weight management26
Neurological and mental health16
Cognitive health4
Cardiovascular3
Metabolic health2

Registered clinical trials

3 of 9 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 11 · Withdrawn: 2
Phase 1: 1 · Phase 1 / Phase 2: 1 · Phase 2: 11

TrialStatusPhaseStartedResults
Study of Tesomet With Open-label Extension in Subjects With Prader-Willi SyndromeNCT05198362WithdrawnPhase 22021-12—
Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)NCT05147415WithdrawnPhase 22021-11—
48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)NCT03845075 · 21 enrolledCompletedPhase 22019-02Posted
Study to Investigate the Pharmacokinetic ProfileNCT03286829 · 60 enrolledCompletedPhase 12017-12Posted
Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)NCT03149445 · 18 enrolledCompletedPhase 22017-03Posted
Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes MellitusNCT02737891 · 60 enrolledCompletedPhase 22016-04Posted
Evaluation of Long Term Safety of Tesofensine in Patients With ObesityNCT00481104 · 140 enrolledCompletedPhase 22007-05—
Effect of Tesofensine on Energy Balance in Humans.NCT00428415 · 32 enrolledCompletedPhase 1, Phase 22007-03—
Effect of Tesofensine on Weight Reduction in Patients With Obesity.NCT00394667 · 200 enrolledCompletedPhase 22006-09—
A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)NCT00148486 · 261 enrolledCompletedPhase 22003-06—
A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor FluctuationsNCT00148512 · 254 enrolledCompletedPhase 22003-03—
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's TypeNCT00153010 · 430 enrolledCompletedPhase 22003-02—
Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's DiseaseNCT00006077 · 50 enrolledCompletedPhase 22000-08—

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease.

    Obesity (Silver Spring, Md.) · March 20, 2008 · Meta-analysis · cited 57 times

    PMID 18356831 · DOI 10.1038/oby.2008.56 · Reviews and meta-analyses

  2. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.

    European journal of endocrinology · May 9, 2022 · Randomized controlled trial · cited 43 times · open access

    PMID 35294397 · DOI 10.1530/eje-21-0972 · Human clinical research

  3. The effect of tesofensine on appetite sensations.

    Obesity (Silver Spring, Md.) · June 30, 2011 · Randomized controlled trial · cited 36 times · open access

    PMID 21720440 · DOI 10.1038/oby.2011.197 · Human clinical research

  4. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.

    Clinical pharmacology and therapeutics · June 2, 2010 · Randomized controlled trial · cited 40 times

    PMID 20520602 · DOI 10.1038/clpt.2010.67 · Human clinical research

  5. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.

    International journal of obesity (2005) · May 18, 2010 · Randomized controlled trial · cited 49 times

    PMID 20479765 · DOI 10.1038/ijo.2010.87 · Human clinical research

  6. Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.

    The AAPS journal · January 15, 2010 · Randomized controlled trial · cited 10 times · open access

    PMID 20077053 · DOI 10.1208/s12248-009-9164-6 · Human clinical research

  7. [The effect of tesofensine on body weight and body composition in obese subjects--secondary publication].

    Ugeskrift for laeger · October 1, 2009 · Randomized controlled trial · cited 5 times

    PMID 19824222 · Human clinical research

  8. A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.

    Clinical pharmacokinetics · January 1, 2009 · Randomized controlled trial · cited 34 times

    PMID 19705923 · DOI 10.2165/11313370-000000000-00000 · Human clinical research

  9. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.

    Lancet (London, England) · October 22, 2008 · Randomized controlled trial · cited 193 times

    PMID 18950853 · DOI 10.1016/s0140-6736(08)61525-1 · Human clinical research

  10. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.

    Archives of neurology · May 1, 2008 · Randomized controlled trial · cited 33 times

    PMID 18474731 · DOI 10.1001/archneur.65.5.577 · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.

    Lancet (London, England) · October 22, 2008 · Randomized controlled trial · cited 193 times

    PMID 18950853 · DOI 10.1016/s0140-6736(08)61525-1 · Human clinical research

  2. Centrally Acting Agents for Obesity: Past, Present, and Future.

    Drugs · July 1, 2018 · Review · cited 150 times · open access

    PMID 30014268 · DOI 10.1007/s40265-018-0946-y · Reviews and meta-analyses

  3. Serotonergic anti-obesity agents: past experience and future prospects.

    Drugs · December 1, 2011 · Review · cited 63 times

    PMID 22085383 · DOI 10.2165/11596680-000000000-00000 · Reviews and meta-analyses

  4. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease.

    Obesity (Silver Spring, Md.) · March 20, 2008 · Meta-analysis · cited 57 times

    PMID 18356831 · DOI 10.1038/oby.2008.56 · Reviews and meta-analyses

  5. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease.

    Movement disorders : official journal of the Movement Disorder Society · February 1, 2007 · Randomized controlled trial · cited 50 times

    PMID 17149725 · DOI 10.1002/mds.21258 · Human clinical research

Latest publications

  1. Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine.

    Drug testing and analysis · June 19, 2026 · Other clinical trial · cited 0 times · open access

    PMID 42320973 · DOI 10.1002/dta.70104 · Human clinical research

  2. Structural basis for pharmacotherapeutic action of triple reuptake inhibitors.

    Nature communications · December 14, 2025 · In vitro study · cited 6 times · open access

    PMID 41392177 · DOI 10.1038/s41467-025-66670-3 · In vitro studies

  3. Sex-specific effects of appetite suppressants on stereotypy in rats.

    PloS one · June 24, 2025 · Animal study · cited 1 times · open access

    PMID 40554466 · DOI 10.1371/journal.pone.0325067 · Animal studies

  4. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons.

    PloS one · April 24, 2024 · Animal study · cited 6 times · open access

    PMID 38656972 · DOI 10.1371/journal.pone.0300544 · Animal studies

  5. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.

    European journal of endocrinology · May 9, 2022 · Randomized controlled trial · cited 43 times · open access

    PMID 35294397 · DOI 10.1530/eje-21-0972 · Human clinical research

  6. Centrally Acting Agents for Obesity: Past, Present, and Future.

    Drugs · July 1, 2018 · Review · cited 150 times · open access

    PMID 30014268 · DOI 10.1007/s40265-018-0946-y · Reviews and meta-analyses

  7. Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET.

    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · October 22, 2013 · Other clinical trial · cited 36 times

    PMID 24239329 · DOI 10.1016/j.euroneuro.2013.10.007 · Human clinical research

  8. Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat.

    Pharmacology, biochemistry, and behavior · August 7, 2013 · Animal study · cited 33 times

    PMID 23932919 · DOI 10.1016/j.pbb.2013.07.018 · Animal studies

  9. Under-reporting of adverse effects of tesofensine.

    Lancet (London, England) · July 1, 2013 · Editorial, letter or other · cited 9 times

    PMID 23849924 · DOI 10.1016/s0140-6736(13)61563-9 · Commentary and other

  10. Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats.

    Obesity (Silver Spring, Md.) · May 1, 2013 · Animal study · cited 22 times · open access

    PMID 23784901 · DOI 10.1002/oby.20122 · Animal studies

Browse all 39 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: NS2330; Tesofensine; TESOFENSINUM

((TITLE_ABS:"NS2330" OR CHEM:"NS2330" OR TITLE_ABS:"NS 2330" OR CHEM:"NS 2330") OR (TITLE_ABS:"Tesofensine" OR CHEM:"Tesofensine") OR (TITLE_ABS:"TESOFENSINUM" OR CHEM:"TESOFENSINUM")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Tesofensine research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/tesofensine